- Home
- IOVA vs LEO Comparison
IOVA vs LEO Comparison
Compare IOVA & LEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- LEO
- Stock Information
- Founded
- IOVA 2007
- LEO 1987
- Country
- IOVA United States
- LEO United States
- Employees
- IOVA N/A
- LEO N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- LEO Trusts Except Educational Religious and Charitable
- Sector
- IOVA Health Care
- LEO Finance
- Exchange
- IOVA Nasdaq
- LEO Nasdaq
- Market Cap
- IOVA 1.0B
- LEO N/A
- IPO Year
- IOVA N/A
- LEO N/A
- Fundamental
- Price
- IOVA $1.73
- LEO $5.95
- Analyst Decision
- IOVA Strong Buy
- LEO
- Analyst Count
- IOVA 9
- LEO 0
- Target Price
- IOVA $18.22
- LEO N/A
- AVG Volume (30 Days)
- IOVA 9.3M
- LEO 200.2K
- Earning Date
- IOVA 05-08-2025
- LEO 01-01-0001
- Dividend Yield
- IOVA N/A
- LEO 4.01%
- EPS Growth
- IOVA N/A
- LEO N/A
- EPS
- IOVA N/A
- LEO 0.04
- Revenue
- IOVA $164,070,000.00
- LEO N/A
- Revenue This Year
- IOVA $182.20
- LEO N/A
- Revenue Next Year
- IOVA $62.10
- LEO N/A
- P/E Ratio
- IOVA N/A
- LEO $152.00
- Revenue Growth
- IOVA 13698.99
- LEO N/A
- 52 Week Low
- IOVA $2.70
- LEO $4.98
- 52 Week High
- IOVA $13.60
- LEO $6.50
- Technical
- Relative Strength Index (RSI)
- IOVA 24.56
- LEO 53.20
- Support Level
- IOVA $3.02
- LEO $5.79
- Resistance Level
- IOVA $3.31
- LEO $5.95
- Average True Range (ATR)
- IOVA 0.24
- LEO 0.07
- MACD
- IOVA -0.08
- LEO 0.03
- Stochastic Oscillator
- IOVA 6.00
- LEO 94.64
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.